Shanghai Kangjing Biopharmaceutical Technology

Shanghai Kangjing Biopharmaceutical Technology (ComGen) is a clinical-stage biotechnology company focused on developing first-in-class therapeutics targeting the complement system. Founded in 2017 and headquartered in Shanghai, the company leverages its proprietary complement-driven drug discovery and efficacy evaluation platforms to address unmet needs in autoimmune diseases, rare diseases, and oncology. Its lead candidate, CG001, is a human-derived C3b-targeted fusion protein currently in Phase 2 clinical trials for paroxysmal nocturnal hemoglobinuria (PNH) and Phase 1 for periodontitis. ComGen's pipeline also includes several antibody and fusion protein candidates targeting various components of the complement cascade, such as C3, C5, and factor B. The company has secured significant funding from top-tier investors like Sequoia China and maintains strategic partnerships with academic and industry leaders like Fudan University and Alphamab Oncology.